Jubilant Biosys Ltd., Bangalore-based subsidiary of Jubilant Life Sciences Ltd, and AstraZeneca, have successfully announced an early stage milestones for a molecule in the pain therapeutic area.
The collaboration, initiated two years ago in the neuroscience therapeutic area, has now expanded to cardiovascular and metabolic diseases. The research now focuses on the delivery of stream of preclinical outcomes to AstraZeneca, by Jubilant.
AstraZeneca owns the compounds developed under the collaboration with worldwide development and commercialization rights. Jubilant derives research funding and success-based development and commercialization milestones.
According to Sri Mosur, CEO & president, Global Drug Discovery & Development, Jubilant, the result of excellent collaboration between scientists at Jubilant and AstraZeneca has enabled the successful delivery of early milestones in drug discovery.
“Partnering is a strategic priority for the UK pharma major at all stages of drug discovery and development,” stated Christof Angst, CNS & Pain Innovative Medicines, vice-president, Strategy and Externalisation, AstraZeneca. “By combining our strengths with those of our partners, we are in a better position to deliver new medicines that can make a meaningful difference to patients’ lives.”
Jubilant Biosys Ltd provides an integrated drug discovery and development solutions to the global pharmaceutical industry. It is engaged in multiple partnerships in therapeutic areas of oncology and CNS.
AstraZeneca is a global, biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease.